Variable | Category | NSAID | Unexposed controls/cases (n) | Exposed controls/cases (n) | OR (95 % CI) | P |
---|---|---|---|---|---|---|
Clinical stage | 1–2 | NSAID (all) | 1170/696 | 739/404 | 0.80 (0.66–0.97 | 0.02 |
Aspirin | 1807/1047 | 102/52 | 0.93 (0.63–1.38) | 0.72 | ||
Acetic acid derivatives | 1753/1025 | 156/74 | 0.75 (0.54–1.06) | 0.11 | ||
Propionic acid derivatives | 1350/770 | 559/329 | 0.90 (0.74–1.11) | 0.33 | ||
cox2 inhibitors | 1891/1095 | 18/4 | - | - | ||
NSAID others | 1861/1072 | 48/27 | 1.07 (0.61–1.90) | 0.81 | ||
3–4 | NSAID (all) | 1170/136 | 739/68 | 0.74 (0.51–1.06) | 0.10 | |
Aspirin | 1807/192 | 102/12 | 1.31 (0.66–2.59) | 0.44 | ||
Acetic acid derivatives | 1753/190 | 156/14 | 0.99 (0.53–1.83) | 0.97 | ||
Propionic acid derivatives | 1350/147 | 559/57 | 0.84 (0.57–1.24) | 0.39 | ||
cox2 inhibitors | 1891/204 | 18/0 | - | - | ||
NSAID others | 1861/201 | 48/3 | - | - | ||
Pathology | Ductal cancer | NSAID (all) | 1170/835 | 739/454 | 0.70 (0.58–0.84) | <0.001 |
Aspirin | 1807/1225 | 102/64 | 0.97 (0.66–1.41) | 0.86 | ||
Acetic acid derivatives | 1753/1204 | 156/85 | 0.76 (0.55–1.06) | 0.11 | ||
Propionic acid derivatives | 1350/918 | 559/371 | 0.78 (0.64–0.95) | 0.01 | ||
cox2 inhibitors | 1891/1289 | 18/3 | - | - | ||
NSAID others | 1861/1259 | 48/30 | 1.06 (0.60–1.87) | 0.85 | ||
Non-ductal cancer | NSAID (all) | 1170/151 | 739/83 | 0.82 (0.58–1.15) | 0.25 | |
Aspirin | 1807/228 | 102/6 | 0.50 (0.21–1.19) | 0.12 | ||
Acetic acid derivatives | 1753/219 | 156/15 | 0.85 (0.46–1.58) | 0.61 | ||
Propionic acid derivatives | 1350/166 | 559/68 | 0.91 (0.63–1.31) | 0.60 | ||
cox2 inhibitors | 1891/234 | 18/0 | - | - | ||
NSAID others | 1861/232 | 48/2 | - | - | ||
Inmunohistochemistry | Hormone + | NSAID (all) | 1170/727 | 739/390 | 0.72 (0.60–0.88) | <0.001 |
Aspirin | 1807/1069 | 102/48 | 0.82 (0.55–1.24) | 0.35 | ||
Acetic acid derivatives | 1753/1044 | 156/73 | 0.76 (0.54–1.08) | 0.12 | ||
Propionic acid derivatives | 1350/805 | 559/312 | 0.80 (0.65–0.98) | 0.03 | ||
cox2 inhibitors | 1891/1115 | 18/2 | - | - | ||
NSAID others | 1861/1089 | 48/28 | 1.28 (0.73–2.25) | 0.38 | ||
HER2+ | NSAID (all) | 1170/739 | 172/83 | 0.63 (0.45–0.88) | 0.007 | |
Aspirin | 1807/102 | 244/11 | 0.79 (0.38–1.65) | 0.53 | ||
Acetic acid derivatives | 1753/238 | 156/17 | 0.67 (0.36–1.24) | 0.20 | ||
Propionic acid derivatives | 1350/188 | 559/67 | 0.66 (0.46–0.95) | 0.03 | ||
cox2 inhibitors | 1891/255 | 18/0 | - | - | ||
NSAID others | 1861/251 | 48/4 | - | - | ||
Triple negative breast cancer | NSAID (all) | 1170/94 | 739/63 | 0.87 (0.58–1.30) | 0.49 | |
Aspirin | 1807/148 | 102/9 | 1.24 (0.57–2.71) | 0.59 | ||
Acetic acid derivatives | 1753/147 | 156/10 | 0.86 (0.41–1.79) | 0.68 | ||
Propionic acid derivatives | 1350/103 | 559/54 | 0.99 (0.64–1.52) | 0.95 | ||
cox2 inhibitors | 1891/156 | 18/1 | - | - | ||
NSAID others | 1861/154 | 48/3 | - | - |